Study on the mechanism of losartan reducing the risk of comorbid depression in epileptic rats
Journal Title: Chinese Journal of Nervous and Mental Diseases - Year 2024, Vol 50, Issue 2
Abstract
[Objective] To investigate the effectiveness and mechanisms of losartan in improving comorbid depression in epileptic rats. [Methods] Male rats were randomly divided into three groups: The losartan-pilocarpine group (PL-L) received intraperitoneal injection of lithium-pilocarpine to establish the epilepsy model, and then followed by losartan intervention. The pilocarpine group (PL) received intraperitoneal injection of lithium-pilocarpine to establish the epilepsy model. The control group (Ctrl) received intraperitoneal injection of lithium chloride. We used the body weight gain and sucrose preference test to analyze the behavior of rats in each group, and RT-PCR was used to examine the expression of High mobility group protein B1 (HMGB1)、interleukin-1β (IL-1β) and interleukin-6 (IL-6) mRNA in hippocampus of rats in each group. [Results] Compared to the Ctrl group, rats in the PL group showed significantly decreased body weight gain [(12.68±5.23) g vs. (41.08±15.87) g, P<0.01] and sucrose preference rate (53.85%±10.14% vs. (88.56%±16.53%, P<0.01). The expression of HMGB1 mRNA (4.17±1.23 vs. 1.00±0.02, P<0.01) was significantly increased. The expression of IL-1β (4.95±1.67 vs. 1.02±0.27, P<0.01) and IL-6 (2.75±1.20 vs. 1.01±0.19, P<0.05) were significantly increased too. Compared with the PL group, rats in the PL group showed significantly increased body weight gain [(37.97±10.24) g vs. (12.68±5.23) g, P<0.01] and sucrose preference rate (77.50%±7.35% vs. 53.85%±10.14%, P<0.05). The expression of HMGB1 (0.76±0.27 vs. 4.17±1.23, P<0.01) was significantly decreased. The expression of IL-1β (0.67±0.21 vs. 4.95±1.67, P<0.01) and IL-6 (0.95±0.27 vs. 2.75±1.20, P<0.05) mRNA were significantly decreased too. [Conclusion] Losartan can reduce the incidence of comorbid depression in epileptic rats, The possible mechanism is that losartan reduces HMGB1 release, so as to reduce the inflammatory factors (IL-1β, IL-6) in the hippocampus of rats. It can reduce the incidence of depression like behavior disorder in rats with epilepsy.
Authors and Affiliations
Nannan PAN, Yachun HU, Xuezhen LIAO, Zhe SHI, Haishan SHI
Keywords
Related Articles
- EP ID EP750427
- DOI 10.3969/j.issn.1002-0152.2024.02.005
- Views 24
- Downloads 0
A comparative study of paradoxical intention therapy and stimulus control therapy in the treatment of insomnia
[Objective] Exploring the therapeutic experience, execution intention, and efficacy of paradoxical intention therapy (PIT) for insomnia among college students compared to stimulus control therapy. [Methods] Eighty-one co...
Advances on the mechanisms of metformin in improving cognitive impairment in schizophrenia
Schizophrenia is a common chronic mental disorder. Cognitive dysfunction is one of its core symptoms , which severely affects the social functioning of patients. Currently, antipsychotic medication treatments have poor e...
Clinical characteristics of 30 patients with intracranial hypotension syndrome
[Objective] To analyze and summarize the clinical presentation of spontaneous and secondary intracranial hypotension syndrome(IHS). [Methods] Patients diagnosed with spontaneous or secondary IHS from September 2022 to Ma...
Cerebellar symptoms and imaging features in neurodegenerative diseases
Pathological, electrophysiological, and neuroimaging changes in the cerebellum can occur in neurodegenerative diseases such as Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis. The activation and n...
Chinese experts consensus on chemotherapy for glioma
Glioma is the most prevalent primary intracranial malignant tumor. At present, the main therapy is surgical resection, supplemented by radiotherapy and chemotherapy. Clinical practice has demonstrated that chemotherapy i...